14 / 24
Summary of efficacy endpoints
0
10
20
30
40
50
60
Olaparib (N=260)
Placebo (N=131)
40.7
Median not reached
15.1
41.9
51.8
51.8
41.9
Median not reached
Median not reached
13.8
41.9
Months since randomization
Median time to
second subsequent
therapy or death
Median time to
first subsequent
therapy or death
Median PFS2
Median PFS
HR 0.45
95% CI 0.32, 0.63;
P<
0.0001
HR 0.30
95% CI 0.22, 0.40;
P<
0.0001
HR 0.50
95% CI 0.35, 0.72;
P=
0.0002
HR 0.30
95% CI 0.23, 0.41;
P<
0.0001